Want to see TSE:RAMM full AI Analyst Report?
RAMM Stock Chart & Stats
C$0.01
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.01
C$0.00(0.00%)
Day’s Range― - ―
52-Week Range<C$0.01 - C$0.25
Previous CloseN/A
Volume1.00K
Average Volume (3M)118.29K
Market Cap
C$1.19M
Enterprise ValueC$866.77K
Total Cash (Recent Filing)C$119.55K
Total Debt (Recent Filing)C$44.17K
Price to Earnings (P/E)―
Beta-3.16
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding119,389,320
10 Day Avg. Volume262,784
30 Day Avg. Volume118,288
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.31
Price to Sales (P/S)0.53
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery light debt provides durable financial flexibility, lowering refinancing and interest-rate pressure. That structural low-leverage position gives management time to execute a turnaround or secure financing on less onerous terms, reducing near-term solvency risk.
Improving Cash Burn TrendA sustained reduction in operating cash outflows signals improved cost control or revenue stabilization. Over a multi-month horizon this trend lowers imminent financing needs and indicates management is making structural adjustments to move toward cash generation.
Narrowing Net LossesMaterial reduction in net losses demonstrates progress closing the gap to breakeven and reflects effective operational or cost actions. If sustained, this structural improvement can stabilize equity, preserve runway, and enable strategic execution over the next several quarters.
Bears Say
Shrinking RevenuePersistent top-line decline undermines scale economics, reduces pricing power and makes fixed-cost absorption harder. Continued revenue contraction over multiple periods is a structural threat to long-term viability unless the company reaccelerates growth or materially cuts cost base.
Deep Negative Margins And Cash BurnExtremely negative margins and recurring negative free cash flow imply the business is not self-sustaining and requires external capital. Over months this structural cash consumption erodes flexibility, forces dilutive financings, and constrains investment in growth or product development.
Eroded Shareholder EquityA sharply reduced equity base leaves little buffer against future losses and increases insolvency risk. This structural erosion limits strategic options, makes future financing more dilutive or costly, and reduces the company's capacity to absorb shocks over the medium term.
Ramm Pharma News
RAMM FAQ
What was Ramm Pharma’s price range in the past 12 months?
Ramm Pharma lowest stock price was <C$0.01 and its highest was C$0.25 in the past 12 months.
What is Ramm Pharma’s market cap?
Ramm Pharma’s market cap is C$1.19M.
When is Ramm Pharma’s upcoming earnings report date?
Ramm Pharma’s upcoming earnings report date is Sep 24, 2026 which is in 52 days.
How were Ramm Pharma’s earnings last quarter?
Ramm Pharma released its earnings results on Jun 30, 2026. The company reported -C$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.002.
Is Ramm Pharma overvalued?
According to Wall Street analysts Ramm Pharma’s price is currently Overvalued.
Does Ramm Pharma pay dividends?
Ramm Pharma does not currently pay dividends.
What is Ramm Pharma’s EPS estimate?
Ramm Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ramm Pharma have?
Ramm Pharma has 119,389,320 shares outstanding.
What happened to Ramm Pharma’s price movement after its last earnings report?
Ramm Pharma reported an EPS of -C$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ramm Pharma?
Currently, no hedge funds are holding shares in TSE:RAMM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ramm Pharma
RAMM Pharma Corp., together with its subsidiaries, operates in the pharmaceutical and medical product business in Uruguay and Poland. The company offers cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other cannabis-based products; and pharmaceuticals, cosmetics, and nutraceutical products. It also engages in the resale of medical supplies products; and the sale of medical devices and consumables. The company was formerly known as MTC Growth Fund-I Inc. and changed its name to RAMM Pharma Corp. in October 2019. RAMM Pharma Corp. was incorporated in 1987 and is based in Toronto, Canada.